MDXG - MiMedx Group, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
3.2200
+0.1200 (+3.87%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close3.1000
Open3.0400
Bid0.0000 x 1000
Ask0.0000 x 800
Day's Range3.0300 - 3.2400
52 Week Range0.9500 - 9.9900
Volume336,250
Avg. Volume556,861
Market Cap352.101M
Beta (3Y Monthly)2.96
PE Ratio (TTM)10.35
EPS (TTM)0.3110
Earnings DateFeb 23, 2018 - Mar 5, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.00
Trade prices are not sourced from all markets
  • Penny Stocks to Watch for May 2019
    Investopedia7 days ago

    Penny Stocks to Watch for May 2019

    May 2019's penny stock winners include low-priced equities that could profit in spite of—and even because of—a market correction.

  • Barrons.com12 days ago

    Activist Raging Capital Sizes Up Tidewater

    Prescience Point Capital Management cut its holding of the regenerative biomaterials maker to 7,618,335 shares on April 29 through May 3. During that span, Prescience acquired 250,000 shares for $2.31 to $2.51 each and sold 603,925 at prices ranging from $2.44 to $2.53 apiece. Prescience now owns nearly 7% of MiMedx’s outstanding stock.

  • PR Newswire13 days ago

    MiMedx Appoints Timothy R. Wright as Chief Executive Officer

    Healthcare Industry Veteran to Lead Next Phase of MiMedx MARIETTA, Ga. , May 9, 2019 /PRNewswire/ -- MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or "the Company"), an industry leader ...

  • Georgia Senator Called VA, FDA, FBI on Behalf of MiMedx CEO
    Bloomberg14 days ago

    Georgia Senator Called VA, FDA, FBI on Behalf of MiMedx CEO

    For help, it turned to a friendly senator in Washington, Johnny Isakson. After the VA said it would no longer purchase medical tissue sold by MiMedx Group Inc., Isakson made at least three phone calls to the agency on behalf of his friend and the company’s chief executive officer, Parker H. Petit, according to two officials who spoke with the senator. One of those officials recounted trying to assuage the senator by explaining that it was an across-the-board policy.

  • PR Newswire15 days ago

    Prescience Point Nominates Slate of Highly-Qualified Director Candidates for Election to MiMedx Board

    BATON ROUGE, La., May 7, 2019 /PRNewswire/ -- Prescience Point Capital Management, LLC, a private investment management firm, together with certain investment partnerships under its management (collectively, "Prescience Point"), today announced that it has nominated a slate of four world-class candidates for election to the MiMedx Group, Inc. ("MiMedx" or the "Company") (MDXG) Board of Directors (the "Board") at the Company's upcoming Annual Meeting of Shareholders (the "Annual Meeting"), scheduled to be held on June 17, 2019. Prescience Point, together with its director nominees, owns approximately 9.98% of the common stock of MiMedx.

  • PR Newswirelast month

    MiMedx Announces Board Approval of Long-Range Strategic Plan

    MARIETTA, Ga., April 11, 2019 /PRNewswire/ -- MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or "the Company"), an industry leader in advanced wound care and an emerging therapeutic biologics company, today reinforced its priorities for 2019 as part of its long-range strategic plan to enhance value for all MiMedx stakeholders.

  • TheStreet.com3 months ago

    Short-Selling Is Really Hard. Just Ask Citron Research

    Examining the influential short-sellers' big winners and losers provides important insights into trading and investing.

  • ACCESSWIRE5 months ago

    Today's Research Reports on Trending Tickers: MiMedx Group and Tandem Diabetes Care

    NEW YORK, NY / ACCESSWIRE / December 12, 2018 / U.S. equities finished lower on Tuesday after bouncing between the red and green territory. The stocks gained more than 1% across the board on improving ...

  • PR Newswire6 months ago

    MiMedx Announces Resignation Of Outside Auditor

    MARIETTA, Ga., Dec. 5, 2018 /PRNewswire/ -- MiMedx Group, Inc. (OTC PINK: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced that on December 4, 2018, Ernst & Young LLP informed the Company's Audit Committee that it has resigned from the engagement to audit the Company's financial statements for the years ended December 31, 2017 and 2018, effective immediately. MiMedx® is a leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. The Company processes the human placental tissue utilizing its proprietary PURION® process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization.

  • PR Newswire6 months ago

    MiMedx Announces Leadership Changes And Promotions

    MARIETTA, Ga., Dec. 5, 2018 /PRNewswire/ -- MiMedx Group, Inc. (OTC PINK: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced certain leadership changes and promotions in conjunction with its plans to implement a broad-based organizational realignment program designed to position the business for long-term success. Additional details regarding the program are available in the Company's press release issued earlier today. "As we continue our efforts to transform our business, we are focused on ensuring that we have the right team and organizational structure in place.

  • PR Newswire6 months ago

    MiMedx Announces Organizational Realignment Program

    MARIETTA, Ga., Dec. 5, 2018 /PRNewswire/ -- MiMedx Group, Inc. (OTC PINK: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced its plans to implement a broad-based organizational realignment, cost reduction and efficiency program to better ensure the Company's cost structure is appropriate given its revenue expectations. MiMedx plans to execute these initiatives while continuing to deliver products and support for healthcare providers and the patients they serve. "Today's announcement is a continuation of management's efforts to position the business for long-term success by focusing on our wound care business, where our clinical studies best support patient outcomes and for which reimbursement policy has traditionally been more stable," said David Coles, Interim Chief Executive Officer.

  • ACCESSWIRE6 months ago

    4 Healthcare Stocks You Should Get To Know Before 2019

    New market trends are pushing investors to pay closer attention to the healthcare industry as it has been seen as a safe haven during turbulent times in the broader markets. In fact, according to the "Cognitive Computing and Artificial Intelligence Systems Market in Healthcare" report from ResearchAndMarkets these technologies have gained significant traction. Increased adoption of cognitive and AI platforms can be attributed to their wide application potential across the healthcare industry, including patients and hospitals.

  • ACCESSWIRE6 months ago

    Today's Research Reports on Trending Tickers: Tandem Diabetes Care and MiMedx

    NEW YORK, NY / ACCESSWIRE / November 8, 2018 / U.S. markets advanced on Wednesday as the midterm election results went according to market expectations. The Democrats took over the House, while the Republicans ...

  • PR Newswire6 months ago

    Jack Henry & Associates Set to Join S&P 500; EQT, Equitrans Midstream, MasTec to Join S&P MidCap 400; Superior Energy Services, United Natural Foods to Join S&P SmallCap 600

    NEW YORK , Nov. 7, 2018 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600: S&P MidCap 400 constituent Jack Henry & Associates Inc. ...

  • Here's Why MiMedx Group Shares Are Imploding 30% Today
    Motley Fool6 months ago

    Here's Why MiMedx Group Shares Are Imploding 30% Today

    The company's shares are being delisted from the Nasdaq exchange tomorrow.

  • MDXG News: MiMedx Stock Plunges on Nasdaq Delisting Notice
    InvestorPlace6 months ago

    MDXG News: MiMedx Stock Plunges on Nasdaq Delisting Notice

    According to MiMedx (NASDAQ:MDXG), its stock will be delisted from Nasdaq at the start of trading tomorrow. The reason for the delisting has to do with the company’s accounting principals not meeting Securities and Exchange Commission (SEC) reporting obligations. The company notes that it doesn’t have any plans to appeal Nasdaq’s decision to delist MiMedx stock from the exchange.

  • PR Newswire6 months ago

    MiMedx Adopts Limited Duration Shareholder Rights Plan In Response To Delisting From Nasdaq

    MARIETTA, Ga., Nov. 7, 2018 /PRNewswire/ -- MiMedx Group, Inc. (MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced that its Board of Directors has unanimously authorized the adoption of a limited duration shareholder rights plan (the "Rights Plan") following receipt of notification from The Nasdaq Stock Market LLC ("Nasdaq") indicating that Nasdaq will suspend trading in the Company's stock effective at the open of business on Thursday, November 8, 2018. Charles R. Evans, Chairman of the Board, said, "The Rights Plan provides the Board with appropriate time to make informed decisions that are in the best long-term interests of MiMedx and our shareholders. The Rights Plan was adopted by the Board following evaluation and consultation with the Company's advisors, and is similar to plans adopted by numerous publicly traded companies.

  • PR Newswire6 months ago

    MiMedx Receives Nasdaq Delisting Notification

    MARIETTA, Ga., Nov. 7, 2018 /PRNewswire/ -- MiMedx Group, Inc. (MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced that it has received notification from The Nasdaq Stock Market LLC ("Nasdaq") indicating that, as a result of the interim progress report submitted by the Company on October 31, 2018, the Nasdaq Hearings Panel (the "Panel") has reconsidered the Company's request for continued listing of the Company's common stock on The Nasdaq Capital Market and has determined that Nasdaq will suspend trading in the Company's stock effective at the open of business on Thursday, November 8, 2018.

  • PR Newswire6 months ago

    MiMedx To Present Clinical And Scientific Studies At Desert Foot Conference

    MARIETTA, Ga. , Nov. 6, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced that five poster abstracts reporting ...